 "Abbott's headquarters at Abbott Park in Illinois, USA")
US pharmaceutical giant Abbott Laboratories' India unit
India banned 344 drug combinations over the weekend, including Abbott's codeine-based cough syrup, after a government panel of experts found they had "no therapeutic justification."
Abbott's Phensedyl cough syrup accounts for about a third of the Indian cough syrup market, and its sales are estimated to make up more than 3% of the company's $1 billion India revenue.
